BVXV Annual EBITDA
-$10.50 M
-$108.00 K-1.04%
31 December 2022
Summary:
As of February 5, 2025, BVXV annual earnings before interest, taxes, depreciation & amortization is -$10.50 million, with the most recent change of -$108.00 thousand (-1.04%) on December 31, 2022. During the last 3 years, it has risen by +$16.25 million (+60.75%).BVXV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV Quarterly EBITDA
-$2.45 M
+$600.00 K+19.69%
30 June 2023
Summary:
As of February 5, 2025, BVXV quarterly earnings before interest, taxes, depreciation & amortization is -$2.45 million, with the most recent change of +$600.00 thousand (+19.69%) on June 30, 2023. Over the past year, it has increased by +$590.90 thousand (+19.44%).BVXV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV TTM EBITDA
-$11.99 M
+$590.90 K+4.70%
30 June 2023
Summary:
As of February 5, 2025, BVXV TTM earnings before interest, taxes, depreciation & amortization is -$11.99 million, with the most recent change of +$590.90 thousand (+4.70%) on June 30, 2023. Over the past year, it has dropped by -$404.60 thousand (-3.49%).BVXV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.0% | +19.4% | -3.5% |
| 3 y3 years | +60.8% | +45.5% | +52.1% |
| 5 y5 years | -7.0% | +62.7% | +50.4% |
BVXV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +3663.1% | -115.0% | -387.2% |
BiondVax Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$2.45 M(-19.7%) | -$11.99 M(-4.7%) |
| Mar 2023 | - | -$3.05 M(-67.1%) | -$12.58 M(+4.7%) |
| Dec 2022 | -$10.50 M(+1.0%) | -$9.27 M(-433.5%) | -$12.01 M(+70.3%) |
| Sept 2022 | - | $2.78 M(-191.5%) | -$7.05 M(-39.1%) |
| June 2022 | - | -$3.04 M(+22.5%) | -$11.58 M(+4.4%) |
| Mar 2022 | - | -$2.48 M(-42.5%) | -$11.09 M(+7.9%) |
| Dec 2021 | -$10.39 M(+3624.4%) | -$4.31 M(+146.6%) | -$10.28 M(-25.9%) |
| Sept 2021 | - | -$1.75 M(-31.4%) | -$13.88 M(-432.6%) |
| June 2021 | - | -$2.55 M(+52.7%) | $4.17 M(+87.1%) |
| Mar 2021 | - | -$1.67 M(-78.9%) | $2.23 M(-23.2%) |
| Dec 2020 | -$279.00 K(-99.0%) | -$7.91 M(-148.5%) | $2.91 M(-187.6%) |
| Sept 2020 | - | $16.31 M(-463.0%) | -$3.32 M(-86.7%) |
| June 2020 | - | -$4.49 M(+352.2%) | -$25.01 M(-3.6%) |
| Mar 2020 | - | -$993.40 K(-93.0%) | -$25.95 M(+7.4%) |
| Dec 2019 | -$26.75 M(+36.3%) | -$14.14 M(+162.6%) | -$24.17 M(+28.2%) |
| Sept 2019 | - | -$5.38 M(-1.0%) | -$18.85 M(+34.2%) |
| June 2019 | - | -$5.44 M(-791.8%) | -$14.05 M(-7.4%) |
| Mar 2019 | - | $785.80 K(-108.9%) | -$15.17 M(-22.2%) |
| Dec 2018 | -$19.63 M | -$8.82 M(+1422.0%) | -$19.51 M(+7.6%) |
| Sept 2018 | - | -$579.40 K(-91.2%) | -$18.14 M(+5.8%) |
| June 2018 | - | -$6.56 M(+84.6%) | -$17.14 M(+51.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$3.55 M(-52.2%) | -$11.29 M(+32.6%) |
| Dec 2017 | -$9.81 M(+340.9%) | -$7.44 M(-1883.5%) | -$8.51 M(+385.4%) |
| Sept 2017 | - | $417.30 K(-158.7%) | -$1.75 M(-34.6%) |
| June 2017 | - | -$711.10 K(-8.3%) | -$2.68 M(+2.9%) |
| Mar 2017 | - | -$775.80 K(+13.4%) | -$2.60 M(+21.4%) |
| Dec 2016 | -$2.23 M(-18.6%) | -$684.20 K(+34.4%) | -$2.15 M(-16.1%) |
| Sept 2016 | - | -$509.00 K(-19.9%) | -$2.56 M(+29.7%) |
| June 2016 | - | -$635.60 K(+100.8%) | -$1.97 M(-8.1%) |
| Mar 2016 | - | -$316.60 K(-71.1%) | -$2.14 M(-4.6%) |
| Dec 2015 | -$2.73 M(+42.6%) | -$1.10 M(-1522.6%) | -$2.25 M(+41.9%) |
| Sept 2015 | - | $77.10 K(-109.5%) | -$1.58 M(-24.7%) |
| June 2015 | - | -$808.30 K(+92.8%) | -$2.10 M(+12.2%) |
| Mar 2015 | - | -$419.30 K(-3.3%) | -$1.87 M(-4.6%) |
| Dec 2014 | -$1.92 M(-3.7%) | -$433.70 K(-1.8%) | -$1.97 M(-3.4%) |
| Sept 2014 | - | -$441.50 K(-23.9%) | -$2.04 M(-2.6%) |
| June 2014 | - | -$580.30 K(+13.7%) | -$2.09 M(+38.4%) |
| Mar 2014 | - | -$510.30 K(+1.5%) | -$1.51 M(+51.1%) |
| Dec 2013 | -$1.99 M(-11.5%) | -$502.90 K(+1.4%) | -$999.00 K(+101.4%) |
| Sept 2013 | - | -$496.10 K | -$496.10 K |
| Dec 2012 | -$2.25 M(+12.3%) | - | - |
| Dec 2011 | -$2.00 M | - | - |
FAQ
- What is BiondVax Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals annual EBITDA year-on-year change?
- What is BiondVax Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals quarterly EBITDA year-on-year change?
- What is BiondVax Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals TTM EBITDA year-on-year change?
What is BiondVax Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BVXV is -$10.50 M
What is the all time high annual EBITDA for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$279.00 K
What is BiondVax Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, BVXV annual earnings before interest, taxes, depreciation & amortization has changed by -$108.00 K (-1.04%)
What is BiondVax Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BVXV is -$2.45 M
What is the all time high quarterly EBITDA for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $16.31 M
What is BiondVax Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, BVXV quarterly earnings before interest, taxes, depreciation & amortization has changed by +$590.90 K (+19.44%)
What is BiondVax Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BVXV is -$11.99 M
What is the all time high TTM EBITDA for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $4.17 M
What is BiondVax Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, BVXV TTM earnings before interest, taxes, depreciation & amortization has changed by -$404.60 K (-3.49%)